Drug Profile
Research programme: IRK4 protein degraders- Kymera Therapeutics
Alternative Names: IRAKIMiDLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Kymera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (PO)
- 30 Oct 2017 Preclinical trials in B- cell lymphoma in USA (PO) (Kymera Therapeutics Pipeline)